AbbVie Inc. vs Bristol-Myers Squibb Company — Stock Comparison
AbbVie Inc. (ABBV) and Bristol-Myers Squibb Company (BMY) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Bristol-Myers Squibb Company narrowly edges AbbVie Inc. on Q·Score (7 vs 6.5 out of 10), led by Quality (8.8 vs 5.5) and Health (6.1 vs 4.9). AbbVie Inc. scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for ABBV (+4.4%) than for BMY (-1.2%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Earnings growing 290% year-over-year on 10% revenue growth.
⚠ balance sheet warrants attention.
High-quality business with 47% return on equity and 19% profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ABBV vs BMY: which stock scores better overall?
Based on Q·Score, Bristol-Myers Squibb Company (BMY) scores 7/10 versus AbbVie Inc. (ABBV) at 6.5/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ABBV or BMY?
AbbVie Inc. (ABBV) scores higher on Growth (8.3/10 vs 8.1/10). AbbVie Inc. reports revenue growth (10.2% YoY) while Bristol-Myers Squibb Company reports (5.7% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ABBV or BMY more attractively valued?
AbbVie Inc. (ABBV) scores higher on Valuation (6.5/10 vs 5.9/10). ABBV trades at 16.3× P/E versus BMY at 10.2×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ABBV vs BMY?
There are 29 analysts covering ABBV with a consensus price target of $276.59, and 24 analysts covering BMY with a consensus target of $66.21. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ABBV or BMY?
Bristol-Myers Squibb Company (BMY) scores higher on Quality (8.8/10 vs 5.5/10). Net profit margin: ABBV at 9.8%, BMY at 18.9%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ABBV or BMY?
Bristol-Myers Squibb Company (BMY) scores higher on Financial Health (6.1/10 vs 4.9/10). Market beta: ABBV at 0.28, BMY at 0.23. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ABBV and BMY?
AbbVie Inc. (ABBV) has a market capitalisation of $468.2B, while Bristol-Myers Squibb Company (BMY) has a market cap of $136.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ABBV or BMY pay dividends?
ABBV pays a dividend yield of 2.61%, while BMY pays a dividend yield of 3.76%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →